Prompt clinical response to secukinumab in patients with axial spondyloarthritis: real-life observational data from three Italian referral centers

Donato Rigante, Stefano Gentileschi, Antonio Vitale, Giuseppe Lopalco, Giacomo Emmi, Gerardo Di Scala, Jurgen Sota, Claudia Fabiani, Bruno Frediani, Mauro Galeazzi, Giovanni Lapadula, Florenzo Iannone, Luca Cantarini

Risultato della ricerca: Contributo in rivistaArticolo in rivista

4 Citazioni (Scopus)

Abstract

Aims: Primary aim of our study was to evaluate short-term efficacy of secukinumab (SCK) in axial spondyloarthritis (axSpA); secondary aims were to identify differences in the clinical and laboratory assessment, according to dosage administered and biologic treatment-lines, and to report any adverse event. Methods: Patients with axSpA consecutively treated with SCK were enrolled. Laboratory assessment was based on erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) evaluation; clinical assessment was performed with the Ankylosing Spondylitis Disease Activity Score (ASDAS)-CRP and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). Data were recorded at baseline and at the 3-month visit. Results: Twenty-one patients (7 males; 14 females) were enrolled; both BASDAI and ASDAS-CRP showed a statistically significant reduction between the baseline and the 3-months visit (p<0.0001 and p=0.0005, respectively). At the laboratory assessment, ESR significantly decreased (p=0.008), while CRP improvement did not reach significance (p=0.213). No statistical significance was observed in BASDAI and ASDAS-CRP improvement (p=0.99 and p=0.69, respectively) and in ESR and CRP variations (p=0.54 and p=0.56, respectively) between patients undergoing SCK 150 mg and subjects administered with SCK 300 mg. No significant differences emerged in the BASDAI, ASDAS-CRP and CRP variations between biologic-naïve patients and subjects previously failing to TNF-α inhibition (p=0.15, p=0.09, p=0.15, respectively). Conversely, ESR decrease was significantly higher in the biologic-naïve subgroup (p=0.01). No adverse events were reported. Conclusions: SCK has proved a remarkable short-term effectiveness regardless the biologic treatment-line, and the dosage of 150 mg confirmed to be appropriate in the clinical and laboratory management of axSpA.
Lingua originaleEnglish
pagine (da-a)438-441
Numero di pagine4
RivistaIsrael Medical Association Journal
Volume2018
Stato di pubblicazionePubblicato - 2018

Keywords

  • Spondyloarthritis

Fingerprint

Entra nei temi di ricerca di 'Prompt clinical response to secukinumab in patients with axial spondyloarthritis: real-life observational data from three Italian referral centers'. Insieme formano una fingerprint unica.

Cita questo